Trulicity Archives -

Novo Nordisk is celebrating the FDA approval of its GLP-1 agonist semaglutide as a treatment for obesity, which

FDA ends 7-year obesity drug drought, clearing Novo Nordisk’s Wegovy

https://pharmaphorum.com/news/fda-ends-obesity-drug-drought/

News/ News/ R&D

Trial win sets up filings for Lilly’s diabetes blockbuster hope tirzepatide

Phil Taylor Diabetes, Eli Lilly, Novo Nordisk, Ozempic, tirzepatide, Trulicity, Type 2 diabetes 0 Comment

Eli Lilly has scored five out of five with its phase 3 trials of type 2 diabetes candidate

Trial win sets up filings for Lilly’s diabetes blockbuster hope tirzepatide

https://pharmaphorum.com/news/final-trial-win-sets-up-filings-for-lillys-diabetes-blockbuster-hope-tirzepatide/

News/ News/ Sales and Marketing

Lilly raises 2020 earnings forecast on pandemic stockpiling

Phil Taylor Basaglar, coronavirus, Eli Lilly, financial results, Humalog, Taltz, Trulicity 0 Comment

Stockpiling of drugs for chronic diseases like diabetes during the coronavirus pandemic lifted Eli Lilly’s first-quarter results, and

Lilly raises 2020 earnings forecast on pandemic stockpiling

https://pharmaphorum.com/news/lilly-raises-2020-earnings-forecast-on-pandemic-stockpiling/

Market Access/ News/ News

FDA approves MACE label claim for Lilly’s Trulicity

Phil Taylor Diabetes, Eli Lilly, Novo Nordisk, Ozempic, Rybelsus, Trulicity 0 Comment

Eli Lilly has firmed up the label for its type 2 diabetes therapy Trulicity with FDA approval for

FDA approves MACE label claim for Lilly’s Trulicity

https://pharmaphorum.com/news/fda-approves-mace-label-claim-for-lillys-trulicity/

News/ News/ Sales and Marketing

Ozempic acceleration buoys Novo Nordisk, and threatens Lilly

Phil Taylor Diabetes, Eli Lilly, financial results, Novo Nordisk, Ozempic, Rybelsus, Saxenda, Trulicity 0 Comment

Solid growth for Novo Nordisk’s weekly GLP-1 agonist Ozempic in the fourth quarter helped the Danish drugmaker beat

Ozempic acceleration buoys Novo Nordisk, and threatens Lilly

https://pharmaphorum.com/news/ozempic-acceleration-buoys-novo-nordisk-and-threatens-lilly/

News/ News/ Sales and Marketing/ Top stories

Lilly’s diabetes med Trulicity shrugs off Novo Nordisk challenge

Phil Taylor Diabetes, Eli Lilly, financial results, Novo Nordisk, Ozempic, Rybelsus, Trulicity 0 Comment

Eli Lilly’s crop of new products propelled the company to 8% sales growth in the fourth quarter, but

Lilly’s diabetes med Trulicity shrugs off Novo Nordisk challenge

https://pharmaphorum.com/news/lillys-diabetes-med-trulicity-shrugs-off-novo-nordisk-challenge/

News/ News/ R&D/ Sales and Marketing

Trulicity helps SGLT-2 patients lower blood sugar

Andrew McConaghie Diabetes, Eli Lilly, Novo Nordisk, Ozempic, Trulicity, Type 2 diabetes 0 Comment

New phase 3b trial results show Lilly’s Trulicity combined with an SGLT2 inhibitor failed to show any benefits above and beyond Trulicity’s blood glucose lowering.

Trulicity helps SGLT-2 patients lower blood sugar

https://pharmaphorum.com/news/trulicity-sglt-2-drug-combo-doesnt-boost-blood-sugar-lowering/

News/ Sales and Marketing

New drugs boost Lilly in Q1 as company hopes for turnaround year

Richard Staines Cymbalta, Diabetes, Jardiance, Lilly, Trulicity 0 Comment

New drugs from Eli Lilly have produced a strong showing in the first quarter, in what could be

New drugs boost Lilly in Q1 as company hopes for turnaround year

https://pharmaphorum.com/transversal-categories/sales-and-marketing/new-drugs-boost-lilly-as-company-hopes-for-turnaround-year/

Trending

Trulicity

Login